Larotrectinib in Treating Patients With Relapsed/Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions
-
Clinical Trial Information
Trial Contact: Spinelli, Jennifer; Armatti, Julie M; Doyle, Katherine M; Dubberly, Paige D; Parker, Melanie
Trial Phone: 321.841.5357 ; 321-843-5284 ; 3218412008 ; 321-841-7561 ; 321-843-1036
-
IRB No: APEC1621A
Protocol Abbrev: APEC1621A
Principal Investigator: Amy A. Smith, MD
Phase: Drug: Phase II
Age Group: Adult;Pediatric
Secondary Protocol No: APEC1621A
Treatment: Drug: Larotrectinib; Drug: Larotrectinib Sulfate
Therapies Involved: Chemotherapy
ClinicalTrials.gov ID: NCT03213704
-
Objective
To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with LOXO-101 (larotrectinib) with advanced solid tumors (including central nervous system [CNS] tumors), non-Hodgkin lymphomas or histiocytic disorders harboring NTRK 1/2/3 fusions.
-
Key Eligibility
Sexes Eligible for Study - All
Ages - 12 Months to 21 Years (Child, Adult)
Accepts Healthy Volunteers - No
